Helicobacter pylori eradication therapy for peptic ulcer can't prevent gastric cancer

A new study shows that treatment of H. pylori may not prevent heterochrony gastric cancer which is from mucosal intestinal metaplasia (IM). The author of the study found no significant change in H. pylori eradication on the carcinogenic effects associated molecular alterations.

Rutgers University Kiron M. Das, PhD, and his colleagues for the first time to clarify the carcinogenic effects of molecular markers in patients with IM, this cross-sectional study included 131 cases underwent endoscopic resection of gastric cancer patients and 22 cases of chronic gastritis in the control group patients. They assessed the MSI (microsatellite instability), hMLH1, CDKN2A and methylation status of APC gene, and the use of monoclonal antibodies (mAb) Das-1 immunoreactivity assessment.

Compared with the control group, MSI and mAb Das-1 reactivity in Helicobacter pylori positive and negative group were significantly increased, suggesting that MSI and mAbDas-1 reactivity associated with the stomach tumor formation (MSI odds ratio, 5.06; mAb Das-1 Reactivity odds ratio 2.51).

Then, the researchers recorded 19 cases of Helicobacter pylori treatment involved in a randomized controlled trial of eradication of patients and 17 cases a year did not eradicate the molecular characterization of changes in a patient marker. The study on December 15, 2015, published online in the British Journal of Cancer, H. pylori eradication no significant reverse change any molecule, including MSI, the primary endpoint, the other methylation status, mAb Das-1 reaction times To the end.

"We are planning further studies to determine the IM phenotype, especially mAb Das-1 phenotypes associated colon, which may facilitate the early identification of high-risk patients," Das said Dr. in an email.

Related reading: http://www.cusabio.com/Polyclonal-Antibody/CD249-Polyclonal-Antibody-11106183.html